Apria's COPD Monitoring
Monitoring Patients to Optimize Treatment
By routinely monitoring the patient’s status, Apria is able to determine if the patient is responding to the prescribed therapy. Monitoring is also very important in determining patient compliance. Our goal is to work with you to optimize care. Click here to learn how easy it is to set up a patient with Apria services.
Ongoing Overnight Oximetries and Education for Patients Not Qualifying for Oxygen Based on Initial Screening
Conducted every 6 months or, per physician’s orders, for up to 24 months
Oximetry at rest and during activities of daily living
Ongoing disease state education
- All Alpha-1 patients are partnered with a dedicated advocate
- Addresses the needs and demands of on-boarding: insurance verification, therapy coverage, financial assistance, and therapy acceptance
- Individualized patient support, lifestyle adjustments, guidance on local support groups, and therapy adherence
- Additional resources: dedicated website, Education Library, Consumer Conference Call Series, and Newsletter
“It is recommended that all subjects with COPD, or asthma characterized by incompletely reversible air flow obstruction should be tested once for AAT deficiency.”1
Statement from the American Thoracic Society and European Respiratory Society
Apria is the only company that offers a complete line of respiratory screening programs including Alpha-1 for your patients with COPD.
Alpha-1 Antitripsyn Deficiency
AAT Deficiency is also called Genetic Emphysema or Genetic COPD
AAT Deficiency can lead to irreversible and progressive damage of lung tissue
The only FDA approved treatment of AAT Deficiency is augmentation therapy or Enzyme Replacement Therapy
The only way to identify AAT carriers or deficient patients is through proper testing
A simple blood test is required
Apria or Coram representatives can help you obtain a complimentary testing kit
AAT serum levels in micromoles. Micromoles <11 is considered deficient
Phenotype and/or Genotype
* All equipment trademarks are properties of their respective owners.
American Thoracic Society/European Respiratory Society Statement: Standards for the Diagnosis and Management of Individuals with Alpha-1 Antitrypsin Deficiency. Am J Respir Crit Care Med. 2003 Oct 1; 168(7): 818-900.
Wencker M, Marx A, Konietzko N, Schaefer B, Campbell EJ. Screening for Alpha-1 Pi deficiency in patients with lung diseases. Eur Respir J. 2002 Aug; 20(2): 319-24.